Which Business Units (e.g., Colostomy, Urology, Wound Care) drove the performance, and were there any notable segment trends?

The short announcement you shared — the invitation to Coloplast’s 9‑month 2024/25 earnings conference call on 19 August 2025 — does not contain the detailed financial or operational breakdown of the company’s performance. Specifically, it does not specify which of Coloplast’s Business Units (e.g., Colostomy, Urology, Wound Care) contributed most to the results, nor does it highlight any segment‑specific trends (such as growth rates, margin changes, or notable market dynamics) for the nine‑month period.

What we can infer from the notice:

What is missing for your specific question:

• Business‑unit contribution (e.g., which segment drove revenue, profit, or growth).
  
• Segment‑level trends (e.g., whether the Colostomy unit saw double‑digit growth, whether Urology sales were flat, or if Wound Care saw a shift in geographic sales).
  
• Quantitative metrics (revenue/EBITDA per unit, growth percentages, margin changes).
  

How to obtain the needed details

1. Review the 9‑Month 2024/25 earnings release (usually a PDF or press release) which will contain a segment‑by‑segment performance table. This table typically shows:

   • Revenue and EBITDA for each Business Unit.
     
   • Year‑over‑year % change.
     
   • Commentary on drivers (e.g., product launches, pricing adjustments, regulatory developments).
     

2. Check the presentation that will be posted on Coloplast’s website (the “Investor Presentation” or “Financial Results Presentation”). These slides often include:

   • A “Business Units performance” slide that highlights the strongest/weakest units.
     
   • Trend charts (e.g., revenue trend for Colostomy, Urology, Wound Care).
     
   • Commentary on market dynamics, new product introductions, or regulatory changes affecting each unit.
     

3. Listen to the conference call recording (available live and on‑demand). The management team typically elaborates on:

   • Which segment(s) drove the overall performance.
     
   • Any notable trends such as:
     
     • Colostomy: growth from new product rollout or expanding market share in North America.
       
     • Urology: impact of pricing adjustments or competitive pressures.
       
     • Wound Care: shifts due to reimbursement changes or new digital health services.
       

4. Read the Q&A segment of the webcast. Analysts often probe deeper on:

   • Expected outlook for each Business Unit.
     
   • Specific challenges or opportunities (e.g., supply‑chain constraints, regulatory approvals).
     

Bottom line

Based solely on the invitation notice, we cannot identify which Business Units drove performance or what segment trends were observed. To answer your question definitively, you’ll need to consult the actual 9‑month interim earnings release, the accompanying investor presentation, and/or the recorded conference‑call discussion and Q&A. Those sources will provide the quantitative and qualitative details you’re seeking. If you obtain those documents and would like help interpreting the data, feel free to share the relevant excerpts, and I can help you summarize the segment performance and trends in detail.